drugset / Trial / NCT01676311

Effects of Huperzine A in Treatment of Moderate to Severe TBI

NCT01676311

Phase 2 Terminated 14 enrolled Spaulding Rehabilitation Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

We will explore the use of Huperzine A in patients who have sustained a moderate to severe Traumatic Brain Injury. We aim to determine whether Huperzine A, as compared with placebo, would have an effect on memory function after TBI. Additionally, we aim to determine whether use of Huperzine A in these patients can change brain activity (as indexed by EEG and Transcranial Magnetic Stimulation - TMS), and reduce prevalence/frequency of post-traumatic seizures. We also aim to evaluate the safety of Huperzine A in this population as compared with placebo.

Timeline

Start
2013-12
Primary completion
2018-08
Completion
2018-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Huperzine A Traditional medicine (herbal / TCM) 600 ug